View source for Riociguat

==Administration==
*Type: Vasodilator
*Dosage Forms: Tab 0.5mg, 1mg, 1.5mg, 2mg, 2.5mg
*Routes of Administration: Oral
*Common Trade Names: Adempas

==Adult Dosing==
===Chronic thromboembolic pulmonary HTN===
*0.5-2.5 mg PO TID
===Pulmonary arterial hypertension===
*0.5-2.5 mg PO TID

==Pediatric Dosing==
Safety/efficacy not established in pediatric patients

==Special Populations==
*[[Drug pregnancy categories|Pregnancy Rating]]: X
*Lactation risk: Avoid Use
===Renal Dosing===
*Adult:
**CrCl >15: No adjustment
**CrCl <15: Not defined
*Pediatric: 
**Safety/efficacy not established in pediatric patients
===Hepatic Dosing===
*Adult:
**Child-Pugh Class A or B: No adjustment
**Child-Pugh Class C: Not definied
*Pediatric:
**Safety/efficacy not established in pediatric patients

==Contraindications==
*Allergy to class/drug
*Pregnancy
*Breastfeeding
*Pulmonary veno-occlusive disease
*Idiopathic interstitial pneumonia

==Adverse Reactions==
===Serious===
*Hemorrhage
*[[Hemoptysis]], severe
*[[Hypotension]], severe

===Common===
*[[Headache]], [[dizziness]]
*[[Gastritis]], dyspepsia, [[GERD]]
*[[Nausea]], [[diarrhea]], [[vomiting]], [[constipation]]
*[[Hypotension]]
*[[Anemia]]

==Pharmacology==
*Half-life: 12h
*Metabolism: Liver extensively; CYP450: 1A1 (primary), 2C8, 2J2, 3A4/5 substrate
*Excretion: Urine 40% (6% unchanged); Feces 53% (15% unchanged)

==Mechanism of Action==
*Sensitizes and stimulates binding of soluble guanylate cyclase to nitric oxide in nitric oxide-sGC-cGMP pathway
*Increases cGMP production and subsequent vasodilation

==Comments==


==See Also==


==References==
<references/>

[[Category:Pharmacology]]